Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero reported a sale of 1,302 shares of common stock on May 18, 2026 at a weighted average price of $5.074 per share. According to the filing, this sale was made to cover tax obligations arising from the release of restricted stock units.
After the transaction, Otero holds 130,088 shares of Lexeo common stock, which includes 100,621 Restricted Stock Units. The trade was reported as a direct ownership transaction and was executed in multiple trades at prices ranging from $5.06 to $5.11 per share.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 3,342 shares of common stock at a weighted average price of $5.0649 per share on May 18, 2026. The footnotes state this sale was made to cover tax obligations arising from the release of restricted stock units, indicating it was a tax-related transaction rather than a discretionary portfolio move. Following the sale, he directly holds 336,764 shares of Lexeo common stock, which includes 252,130 restricted stock units.
LXEO notice under Rule 144 reporting proposed sale of 3,342 shares of common stock tied to restricted stock vesting on 05/15/2026. The filing also lists a prior sale of 10,173 shares by Richard N. Townsend on 02/18/2026.
LXEO filing a Form 144 notice for proposed resale of Common Stock following a restricted stock vesting event dated 05/15/2026. The filing lists a broker Fidelity Brokerage Services LLC and shows a recent reported disposition of 3,016 shares on 02/18/2026.
LXEO filed a Form 144 notice relating to 1,595 shares of Common Stock tied to restricted stock vesting on 05/15/2026. The filing also lists prior sales of 4,867 shares on 02/18/2026 attributed to Eric Adler with an associated value of 31,135.17.
Lexeo Therapeutics Schedule 13G/A Amendment No. 2 reports beneficial ownership disclosures by Paradigm-related reporting persons as of the close of business on March 31, 2026. Paradigm BioCapital Advisors (and affiliated entities) report 6,184,134 shares (8.3%) and Paradigm BioCapital International Fund Ltd. reports 5,449,272 shares (7.4%). The filing states the ownership percentages are calculated using 74,086,737 shares outstanding as of March 31, 2026.
Lexeo Therapeutics, Inc. Schedule 13G/A reports that Balyasny Asset Management and related entities beneficially own 7,176,144 shares of Common Stock, representing 9.69% of the class. The filing states this position includes 5,586,529 shares issuable upon exercise of warrants subject to a "Beneficial Ownership Limitation," and cites 74,087,063 shares outstanding as of March 27, 2026.
The filing lists voting and dispositive authority as sole for the reported shares and identifies the reporting persons as Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny. ADMF and APHC are named as the direct holders on whose behalf the reporting persons report ownership.
Lexeo Therapeutics’ quarterly report shows a smaller loss and a solid cash position as it advances gene therapy programs for cardiovascular disease. For the three months ended March 31, 2026, net loss was $20.2 million, improved from $32.7 million a year earlier, as operating expenses fell to $22.3 million from $33.8 million.
The company reported cash, cash equivalents and investments in U.S. Treasury securities of $227.6 million and total assets of $250.4 million, with an accumulated deficit of $400.3 million. Management believes this cash balance will fund operations for at least 12 months, though additional capital will be needed longer term.
Lexeo Therapeutics reported first quarter 2026 results alongside detailed pipeline updates in an 8-K and investor presentation. The company posted a net loss of $20.2 million, or $0.25 per share, an improvement from a $32.7 million loss a year earlier, driven partly by sharply lower general and administrative expenses.
Cash, cash equivalents and marketable securities were $227.6 million as of March 31, 2026, which Lexeo believes will fund operations into 2028. The update highlights progress for lead cardiac gene therapy programs LX2006 in Friedreich ataxia cardiomyopathy and LX2020 in PKP2 arrhythmogenic cardiomyopathy, including ongoing pivotal‑trial preparations and additional clinical data, and notes a new independent director appointment.
Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $5.81 per share and expire on April 27, 2036. They vest in equal annual installments over three years, so the award becomes fully exercisable on the third anniversary of the grant date, subject to her continuous service with the company. After this grant, she holds options for 50,000 underlying shares directly.